Founded
31 Dec 2001
Address
Visiogen Inc
2 Goodyear Suite B
Irvine, CA 92618
United States
Phone
Website
Business classification
VCID: 127173
Profile
Corporate information
Official name
Visiogen Incorporated
Registration country
Official identities
US CIK 0001144346
Investment activity status
Active investor
Company type
A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss.Funding
Funding rounds
Acquisition USD 400,000,000
USD 400,000,000 (3 Oct 2009) at USD 400,000,000 valuation.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Abbott Laboratories | United States | USD 400,000,000 (USD 400,000,000). Initial investment. Round participant. |
Series D USD 40,000,000
USD 40,000,000 (1 May 2009)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
CMEA Capital | United States | Initial investment. Round participant. | |
|
Foundation Medical Partners | United States | Initial investment. Round participant. | |
|
New Leaf Venture Partners | United States | Initial investment. Round participant. | |
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | Switzerland | Initial investment. Round participant. |
|
Prospect Venture Partners | Venture capital firm | United States | Initial investment. Round participant. |
|
Technology Partners. | Venture capital firm | United States | Initial investment. Round participant. |
|
Three Arch Partners LP | Venture capital firm focused on healthcare, medical devices, diagnostics, healthcare services, and biotechnology sectors. | United States | Initial investment. Round participant. |
N/A USD 24,000,000
USD 24,000,000 (1 Feb 2007)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
CMEA Capital | United States | Initial investment. Round participant. |
Venture USD 16,500,000
USD 16,500,000 (1 Dec 2003)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
Prospect Venture Partners | Venture capital firm | United States | Initial investment. Round participant. |
|
The Sprout Group | Venture capital affiliate of Credit Suisse | United States | Initial investment. Round participant. |
|
|
Three Arch Partners LP | Venture capital firm focused on healthcare, medical devices, diagnostics, healthcare services, and biotechnology sectors. | United States | Initial investment. Round participant. |
Series B USD 5,000,000
USD 5,000,000 (1 Jul 2002)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
The Sprout Group | Venture capital affiliate of Credit Suisse | United States | Initial investment. Round participant. |
|
|
Three Arch Partners LP | Venture capital firm focused on healthcare, medical devices, diagnostics, healthcare services, and biotechnology sectors. | United States | Initial investment. Round participant. |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Pinnacle Ventures LLC | Venture capital firm that focuses on providing debt and equity financing to growing companies. | United States |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Abbott Laboratories |
+1 (847) 937-6100 |
Acquisition |
|
|
CMEA Capital |
+1 (415) 352-1520 |
N/A Series D |
|
|
Foundation Medical Partners |
+1 (203) 851-3900 |
Series D |
|
|
New Leaf Venture Partners |
+1 (646) 871-6400 |
Series D |
|
Novartis Services Inc |
+1 (617) 871-3536 |
N/A |
|
|
Novartis Venture Funds The corporate venturing arm of Novartis. |
+41 (61) 324-6210 |
Series D |
|
|
Pinnacle Ventures LLC Venture capital firm that focuses on providing debt and equity financing to growing companies. |
+1 (650) 926-7800 |
N/A |
|
|
Prospect Venture Partners Venture capital firm |
+1 (650) 327-8800 |
Series D Venture |
|
|
Technology Partners. Venture capital firm |
+1 (650) 289-9000 |
Series D |
|
|
The Sprout Group Venture capital affiliate of Credit Suisse |
Series B Venture |
|
|
|
Three Arch Partners LP Venture capital firm focused on healthcare, medical devices, diagnostics, healthcare services, and biotechnology sectors. |
+1 (650) 529-8000 |
Series B Series D Venture |